Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: Correlation with clinicopathological parameters

Breast

Volumn 19, Issue 6, 2010, Pages 489-492

  Farzadnia, Mehdi ^a   Meibodi, Naser Tayyebi ^a   Shandiz, Fatemeh Homayi ^b   Mahmoudi, Mahmoud ^b   Bahar, Mostafa Mehrabi ^b   Memar, Bahram ^a   Amoian, Sakineh ^a   Maroozi, Farshad ^a   Moheghi, Nasrin ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast carcinoma; ELISA; Immunohistochemistry; Serum HER2 neu

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; TUMOR VOLUME;

EID: 78349309754     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.05.012     Document Type: Article

References (27)

1. Ludovini V., Gori S., Colozza M., et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol 2008, 19(5):883-890.
2. Bramwell V.H., Doig G.S., Tuck A.B., et al. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Breast Cancer Res Treat 2009, 114(3):503-511.
3. Disis M.L., Gralow J.R., Bernhard H., Hand S.L., Rubin W.D., Cheever M.A. Peptide based but not whole protein vaccines elicit immunity to HER2/neu, oncogenic self protein. J Immunol 1996, 156(9):3151-3158.
4. Ring C.J., Blouin P., Martin L.A., Hurst H.C., Lemoine N.R. Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes drive tumor-selective expression of a prodrug activating enzyme. Gene Ther 1997, 4(10):1045-1052.
5. Batra J.K., Kasprzyk P.G., Bird R.E., Pastan I., King C.R. Recombinant anti-erbB2 immunotoxins containing pseudomonas exotoxin. Proc Natl Acad Sci USA 1992, 89(13):5867-5871.
6. Zhang L., Lau Y.K., Xia W., Hortobagyi G.N., Hung M.C. Tyrosine kinase inhibitor emodin suppresses growth of HER-2 over-expressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res 1999, 5:343-353.
7. Carney W.P., Neumann R., Lipton A., Leitzel K., Ali S., Price C.P. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 2003, 49(10):1579-1598.
8. Luftner D., Luke C., Possinger K. Serum HER2/neu in the management of breast cancer patients. Clin Biochem 2003, 36:233-240.
9. Tse C., Brault D., Gligorov J., et al. Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients. Clin Chem 2005, 51(7):1093-1101.
10. Hudelist G., Köstler W.J., Gschwantler-Kaulich D., et al. Serum EGFR levels and efficacy of trastuzumab based Therapy in patients with metastatic breast cancer. Europian Journal of Cancer 2006, 42:186-192.
11. Kushlinskii N.E., Shirokii V.P., Gershtein E.S., Yermilova V.D., Chemeris G.Y., Letyagin V.P. Soluble fragment of HER2/neu receptor in the serum of patients with breast cancer with different levels of this protein expression in the tumor. Bull Exp Biol Med 2007, 143(4):449-451.
12. Kong S.Y., Nam B.H., Lee K.S., et al. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin Chem 2006, 52(8):1510-1515.
13. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\neu oncogen. Science 1978, 235:177-182.
14. Dati C., Muraca R., Tazartes O., et al. C-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. Int J Cancer 1991, 47:833-888.
15. Ali I.U., Campbell G., Lidereau R., Callahan R. Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma. Oncog Res 1988, 3:139-146.
16. Guerin M., Barrois M., Terrier M.J., Spielmann M., Riou G. Over-expression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncog Res 1988, 3:21-31.
17. Clark G.M., McGuire W.L. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991, 51:944-948.
18. Yuan P., Xu B.H., Zhang C., Qi J. Serum her-2/neu level and related factors in patients with breast cancer. Zhongua Zhong Liu Za Zhi 2003, 25(6):573-574.
19. Imoto S., Kitoh T., Hasebe T. Serum C-erbB-2 levels in monitoring of operable breast cancer patients. Japn J Clin Oncol 2007, 29(7):336-339.
20. Yang J., Xing T., Yao X., Hu R. Relationship of C-erbB-2 oncogene overexpression to estrogen progestrone receptors in breast cancer and its prognostic significance. Hua Xi Yi Ke Da Xue Bao 1997, 28:214-217.
21. Abadjian G., Antoun R. Breast carcinoma: evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers. J Med Liban 1996, 44:10-15.
22. Molina R., Ciocca D.R., Tandon A.K., et al. Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and Western blot techniques. Anti-cancer Res 1992, 12:1965-1971.
23. Rilke F., Colnaghi M.I., Cascinelli N., et al. Prognostic significance of Her-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991, 49:44-49.
24. van de Vijver M.J., Peterse J.L., Mooi W.J., et al. Neu-protein over-expression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988, 319:1239-1245.
25. Gullick W.J., Love S.B., Wright C., et al. C-erbB-2 Protein over-expression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991, 63:434-438.
26. Choi D.H., Shin D.B., Lee M.H., et al. A comparison of five immunohistochemical biomarkers and HER2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer 2003, 98:1587-1595.
27. Rampaul R.S., Pinder S.E., Gullick W.J., Robertson J.F.R., Ellis I.O. HER2/neu in breast cancer-methods of detection, clinical significance and future prospects for treatment. Crit Rev Oncol Hematol 2002, 43:231-244.